Company Overview and News
New Delhi: The National Company Law Appellate Tribunal (NCLAT) on Wednesday asked Eveready Industries to pay more than Rs17.1 crore in connection with an appeal moved by the company against a Rs171.55 crore penalty imposed on it by the Competition Commission of India (CCI) for cartelisation in pricing of zinc-carbon dry cell batteries.
Shares of Eveready plunged nearly 11 per cent a day after fair trade regulator CCI imposed a fine of Rs 171.55 crore on the company for cartelisation in pricing of zinc-carbon dry cell batteries.
2:35 pm TCS eyes USD 100 billion in market cap: TCS is the most valued company at Dalal Street, with a market capitalisation of Rs 6.5 lakh crore and inching towards to become the first USD 100 billion company after its healthy earnings performance and strong commentary.
12:45 pm Market Update: The market remained under selling pressure following negative lead from global stocks. But the sharp rally in technology stocks post TCS' Q4 FY18 result and a weak rupee continued to support benchmark indices.
11:50 am Market Update: The market remained under selling pressure due to global weakness, but the sharp rally in technology stocks post TCS Q4 results and weak rupee capped the losses of benchmark indices.
10:55 am Buzzing: Eveready Industries plunged 10 percent after fair trade regulator CCI imposed a total fine of Rs 215 crore on Eveready as well as Indo National, industry grouping AIDCM and their officials for cartelisation in pricing of zinc carbon dry cell batteries.
New Delhi : Fair trade regulator CCI on Thursday imposed a total fine of Rs 215 crore on Eveready, Indo National, industry grouping AIDCM and their officials for cartelisation in pricing of zinc carbon dry cell batteries.
Fair trade regulator CCI today imposed a total fine of Rs 215 crore on Eveready, Indo National, industry grouping AIDCM and their officials for cartelisation in pricing of zinc carbon dry cell batteries.
The company’s standalone revenue stood at Rs. 544.72 crore, up 10.87% yoy but down 11.8% ...
Manish Sharma has become the first Indian to be appointed as Executive Officer, Panasonic Corporation, the company said in a statement.
14h - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
14h - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...